Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer
Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more potently than wild-type EGFR. Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | engleski |
| Izdano: |
2015
|
| Online pristup: | https://doi.org/10.1158/2159-8290.cd-15-0063 https://cancerdiscovery.aacrjournals.org/content/candisc/5/9/960.full.pdf |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|